This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
Acute ischemic stroke with moderate to severe hemiparesis
Functional independence in activities of daily living without requiring nursing care before the index stroke.
Consent process by participant or proxy, with reconsent provision.
Age ≥ 45 to ≤ 80 years of age (inclusive) on the date of randomization
Pre-existing motor deficit prior to index stroke
Posterior circulation ischemic stroke
Lacunar stroke
Qualifying brain imaging demonstrating intracranial hemorrhage, malignant middle cerebral artery (MCA) infarct with edema, or bilateral/multifocal infarcts, clinically significant vascular malformation, brain tumor, or other central nervous system (CNS) pathology